David Schaaf
Hoofd Techniek/Wetenschap/O&O bij PDS BIOTECHNOLOGY CORPORATION
Profiel
David Schaaf is currently the Vice President-Medical Affairs at PDS Biotechnology Corp.
He previously worked as the Vice President-Medical Affairs at Zogenix, Inc. Schaaf has a graduate degree from The Trustees of Columbia University in The City of New York and an undergraduate degree from Stanford University.
Actieve functies van David Schaaf
| Bedrijven | Functie | Begin |
|---|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Hoofd Techniek/Wetenschap/O&O | 01-09-2022 |
Eerdere bekende functies van David Schaaf
| Bedrijven | Functie | Einde |
|---|---|---|
| ZOGENIX, INC. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van David Schaaf
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| Stanford University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PDS BIOTECHNOLOGY CORPORATION | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
